Misawa N, et al. - Among 29 consecutive patients (57 eyes) with treatment-naïve Vogt-Koyanagi-Harada (VKH) disease, researchers explored the connection between visual prognosis and human leukocyte antigen (HLA)-DRB1*04 alleles during systemic corticosteroid therapy. Linear regression demonstrated significant variations in logMAR best-corrected visual acuity between the three groups of homozygotes, heterozygotes, and normal individuals at baseline, at 3 months after treatment. No significant differences were found at 6 months after treatment. There were no significant differences between the three groups in age, gender, refractive error, central retinal thickness, central choroidal thickness, or duration from onset to treatment. According to this retrospective case series, alleles of HLA-DRB1*04 could affect the visual prognosis and be associated with the early response after initiation of VKH disease treatment.